EMBOGUARD™ is the first balloon guide catheter from CERENOVUS and the latest device to join the CERENOVUS Stroke Solutions™ suite of technologies in Europe
GALWAY, IE – September 5, 2024 – CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced the launch of EMBOGUARD™, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.
Ischemic strokes, caused by the formation of a local blood clot or an embolus that travels to a vessel in the brain and obstructs blood supply, account for 85%1 of all strokes worldwide. Mechanical thrombectomy (MT), a minimally invasive procedure to remove a clot, is the recommended treatment option for acute ischemic stroke.2
The EMBOGUARD™ Balloon Guide Catheter is designed to optimize removal of clots by controlling blood flow locally during MT procedures.3 Balloon guide catheters increase first pass recanalization, reduce procedure time and reduce the odds of clot fragments breaking off and causing distal emboli.4 Distal emboli in an endovascular procedure can result in new ischemic events.
“Timely and effective treatment of stroke patients is critical to reducing lifelong disability or dependency,” said Dr. Levansri Makalanda*, Lead Consultant for Interventional Neuroradiology at Barts Health NHS Trust. Dr. Makalanda and the team at Barts Health were the first Clinical users of the EMBOGUARD device in Europe. “We are big believers in using the most modern and evidence-based technology for patient specific care. For us here in Barts and others within the speciality the benefits of balloon guide catheters are recognised for their ability to maximize patient outcomes. The second generation BGCs are game changers - allowing large bore Distal Access Catheters to be delivered to the intracranial circulation. With the largest inner diameter EMBOGUARD allows this in a flexible form and without compromise, thereby improving the chances to live a functional and fulfilling life post-stroke.”
EMBOGUARD™ is the latest addition to join CERENOVUS Stroke Solutions™, a suite of technologies designed with compatibility in mind to assist physicians in performing mechanical thrombectomy procedures. CERENOVUS Stroke Solutions now includes the EMBOTRAP™ III Revascularization Device, the PROWLER™ Select Plus 160, the CEREGLIDE 71™ with TruCourse™ as well as both the EMBOGUARD™ Balloon Guide Catheter and the CEREBASE™ Guide Sheath.
“We’re proud to announce the addition of EMBOGUARD into our family of CERENOVUS Stroke Solutions here in Europe,” said Mark Dickinson, Worldwide President, CERENOVUS. “The addition of this device to our portfolio of technologies provides physicians with an innovative and comprehensive set of tools to treat their patients, building on our commitment to changing the trajectory of stroke.”
For more information about CERENOVUS, connect with us on Twitter and LinkedIn.
About CERENOVUS
CERENOVUS, Inc., part of Johnson & Johnson MedTech, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit cerenovus.com and connect on LinkedIn and X.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more information, visit J&J MedTech.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding CERENOVUS EMBOGUARD™. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of CERENOVUS, Medical Device Business Services, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither CERENOVUS, Medical Device Business Services, Inc., any of the other Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
*CERENOVUS, Inc. is a part of Johnson & Johnson MedTech which comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment
**Dr Levansri Makalanda was not compensated for his contributions
- Ischaemic stroke. Stroke Association. Stroke.org.uk.
- Parthasarathy R and Gupta V. Ann Indian Acad Neurol. 2020 Jan-Feb 23(1): 13–19. ncbi.nlm.nih.gov. Last accessed online September 2020.
- EMBOGUARD Simulated Clot Retrieval Report. 500756583 | Rev: A.6. Released: 15-Jul-2021. State: Released. CN: 231147
- Brinjikji, Waleed, et al. Impact of balloon guide catheter on technical and clinical outcomes: a systematic review and metaanalysis. J NeuroIntervent Surg. 2017. jnis.bmj.com.
Media contact:
Anna Loring
+447736180038
[email protected]
EM_CNV_ACSS_389412